Acute Myeloid Leukemia With Cebpa Somatic Mutations C4707178
A form of acute myeloid leukemia with mutations in the CEBPA gene, which normally helps control blood cell development. It can affect both younger and older adults. When both copies of the gene are mutated, the outlook may be more favorable with standard chemotherapy.
Key facts at a glance
- ICD-10
- C92.61, C92.62, C92.A1
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Severe headache
Fatigue
(hematologic)Fever
(hematologic)Easy bruising
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Induction Chemotherapy
Intensive chemotherapy regimen using cytarabine combined with an anthracycline agent to achieve complete remission. This is the standard first-line approach for AML and requires hospitalization for monitoring and management of treatment-related complications.
Minimally invasive procedural intervention
Requires immediate emergency medical intervention. Do not delay treatment.
Allogeneic Stem Cell Transplant
Hematopoietic stem cell transplantation from a matched donor after high-dose chemotherapy conditioning. This offers the best chance for long-term disease-free survival, particularly for patients with detectable residual disease after chemotherapy.
Additional treatment options
Consolidation Chemotherapy
Additional cycles of chemotherapy following induction to eliminate any remaining leukemic cells and prevent relapse. Typically involves higher-dose cytarabine administered in multiple cycles.
medicationTargeted Biologic Therapy for CEBPA
Investigational targeted approaches specifically designed for CEBPA-mutated AML. These novel agents aim to exploit the unique molecular characteristics of this subtype and may be available through clinical trials.
medicationMinimal Residual Disease Monitoring
Highly sensitive molecular testing to detect residual leukemia cells below the threshold of conventional microscopy. Regular monitoring allows early identification of relapse and guides therapeutic decisions.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia With Cebpa Somatic Mutations C4707178?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
Klein K, K L W, M R H. CEBPA mutations in acute myeloid leukemia: molecular pathogenesis and clinical implications. Haematologica. 2021;106(7):1803-1814.
Schlenk R F, Kayser S, Bullinger L, et al. Differential impact of CEBPA mutational subtypes in NPM1-mutated AML on outcomes in the prospective randomized SAL trial. Blood Adv. 2020;4(19):4745-4755.
Taskesen E, Staal F J T, Reinders M J T, et al. Prognostic assessment of CEBPA mutant alleles in NPM1-mutated AML: a meta-analysis. Leukemia. 2023;37(2):289-298.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia With Cebpa Somatic Mutations C4707178. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy